Study of characteristics and complications in young patients with myeloproliferative neoplasia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a national database that captures the clinico-biological characteristics and complications of myeloproliferative neoplasia in patients under 30 years old. By collecting and analyzing data from these patients, the study seeks to provide a clearer understanding of their care and outcomes. Additionally, it will facilitate the identification of biological samples available in routine laboratories, allowing researchers to conduct further analyses to refine diagnoses and explore new molecular prognostic factors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient diagnosed with non-LMC MPN before the age of 30 (PV or TE or MFP or PreMF) according to the 2016 WHO criteria.
* Signature of the consent form for participation in the FIMBANK project.
* Agreement to participate in the VYP study.
* Patient of legal age at the time of inclusion in VYP.
* Patient affiliated to a social security scheme

Exclusion Criteria:

* Refusal to participate by patients of full age
* Patient under legal protection (guardianship, curatorship, etc.)

Where it's running

• CHU de Brest
  Brest, France Recruiting

Study contacts

• Study coordinator: Jean-Christophe IANOTTO
• Email: jean-christophe.ianotto@chu-brest.fr
• Phone: 0298223786

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Caris Chromoseq data collection for AML, MDS, and MPN

  This study tests how well the Caris Chromoseq assay helps categorize risk in patients with AML, MDS, or MPN compared with standard tests.

  Recruiting Caris Science, Inc. · Phoenix, Arizona · NCT07680868

• Using NETosis blood markers to predict clot risk in JAK2-positive myeloproliferative neoplasms

  This study will try to see if blood markers of NETosis can predict clotting risk in people with JAK2V617F-positive myeloproliferative neoplasms who are at high risk for thrombosis.

  Recruiting University Hospital, Bordeaux · Angers and 14 other locations · NCT07119970

• CMV Triplex vaccine to boost immunity and prevent CMV after haploidentical stem cell transplant

  This trial tests whether giving a CMV-MVA Triplex vaccine to donors and/or recipients, with or without the antiviral letermovir, can boost CMV immunity and prevent CMV viremia in people having haploidentical stem cell transplants.

  Recruiting at 3 sites Phase 1 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07020533

• Vedolizumab with post-transplant cyclophosphamide and short-course tacrolimus to prevent graft-versus-host disease after reduced-intensity allogeneic stem cell transplant

  This trial tests whether adding vedolizumab to post-transplant cyclophosphamide and a short course of tacrolimus can prevent graft-versus-host disease in adults getting reduced-intensity allogeneic stem cell transplants for leukemias or related blood disorders.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT06815003

• Using Sorafenib to Prevent Relapse After Stem Cell Transplantation

  This study is testing if the drug sorafenib can help prevent relapse in patients with high-risk blood cancers after they receive a stem cell transplant.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06532084

• Understanding the risks of thrombosis in CALR-mutated MPN patients

  This study is trying to understand why people with CALR mutations in myeloproliferative neoplasms have a different risk of blood clots compared to those with JAK2 mutations by looking at certain blood markers.

  Recruiting at 2 sites Wake Forest University Health Sciences · Charlotte, North Carolina and 1 other locations · NCT06480591

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.